Development of Interpretive Breakpoints for Antifungal Susceptibility Testing: Conceptual Framework and Analysis of In Vitro-In Vivo Correlation Data for Fluconazole, Itraconazole, and Candida Infections
John Rex(AstraZeneca (Brazil)), A L Barry, Frank C. Odds(Radboud University Nijmegen), M. Lancaster, Thomas J. Walsh(Cornell University), Ana Espinel‐Ingroff, Mahmoud A. Ghannoum(Case Western Reserve University), Marilyn S. Bartlett, J N Galgiani, Michael G. Rinaldi, Michael A. Pfaller(University of Iowa)
Cited by 863
Related Papers
Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
|Clinical Infectious Diseases|2008|4.9k
Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America
|Clinical Infectious Diseases|2015|4k
Clinical Practice Guidelines for the Management Candidiasis: 2009 Update by the Infectious Diseases Society of America
|Clinical Infectious Diseases|2009|3.2k
Epidemiology and Outcome of Zygomycosis: A Review of 929 Reported Cases
|Clinical Infectious Diseases|2005|3k
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America
|Clinical Infectious Diseases|2016|2.8k